In this cohort, we were able to evaluate the relationship of CAIX expression with the KRAS mutational status which proved to be correlated, as KRAS mutant rectal adenocarcinomas presented initially and following neoadjuvant therapy with significantly higher CAIX scores and CAIXhigh phenotype. This evidence concerns the gene KRAS and rectum adenocarcinoma.